X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Elder Pharma with Dishman Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs DISHMAN PHARMA - Comparison Results

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ELDER PHARMA DISHMAN PHARMA ELDER PHARMA/
DISHMAN PHARMA
 
P/E (TTM) x -0.2 25.1 - View Chart
P/BV x 0.1 3.3 3.0% View Chart
Dividend Yield % 0.0 0.7 -  

Financials

 ELDER PHARMA   DISHMAN PHARMA
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
DISHMAN PHARMA
Mar-16
ELDER PHARMA/
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs380374 101.5%   
Low Rs188129 145.8%   
Sales per share (Unadj.) Rs491.2197.8 248.3%  
Earnings per share (Unadj.) Rs-3.221.2 -15.0%  
Cash flow per share (Unadj.) Rs14.434.7 41.5%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs376.5179.9 209.3%  
Shares outstanding (eoy) m20.5480.69 25.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.61.3 45.4%   
Avg P/E ratio x-89.311.9 -752.2%  
P/CF ratio (eoy) x19.77.2 272.0%  
Price / Book Value ratio x0.81.4 53.9%  
Dividend payout %09.4 0.0%   
Avg Mkt Cap Rs m5,83320,306 28.7%   
No. of employees `000NA0.8 0.0%   
Total wages/salary Rs m2,1795,355 40.7%   
Avg. sales/employee Rs ThNM19,252.7-  
Avg. wages/employee Rs ThNM6,459.5-  
Avg. net profit/employee Rs ThNM2,064.1-  
INCOME DATA
Net Sales Rs m10,08915,961 63.2%  
Other income Rs m257265 96.7%   
Total revenues Rs m10,34616,226 63.8%   
Gross profit Rs m-7924,103 -19.3%  
Depreciation Rs m3611,091 33.1%   
Interest Rs m2,756944 291.9%   
Profit before tax Rs m-3,6532,334 -156.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m3,7130-   
Tax Rs m125624 20.1%   
Profit after tax Rs m-651,711 -3.8%  
Gross profit margin %-7.825.7 -30.5%  
Effective tax rate %-3.426.7 -12.8%   
Net profit margin %-0.610.7 -6.0%  
BALANCE SHEET DATA
Current assets Rs m9,24011,018 83.9%   
Current liabilities Rs m9,9989,517 105.1%   
Net working cap to sales %-7.59.4 -79.9%  
Current ratio x0.91.2 79.8%  
Inventory Days Days46110 41.9%  
Debtors Days Days6035 172.1%  
Net fixed assets Rs m10,12416,304 62.1%   
Share capital Rs m206161 127.4%   
"Free" reserves Rs m5,58212,907 43.3%   
Net worth Rs m7,73414,516 53.3%   
Long term debt Rs m4,8894,189 116.7%   
Total assets Rs m22,88229,805 76.8%  
Interest coverage x-0.33.5 -9.4%   
Debt to equity ratio x0.60.3 219.0%  
Sales to assets ratio x0.40.5 82.3%   
Return on assets %11.88.9 132.0%  
Return on equity %-0.811.8 -7.2%  
Return on capital %22.317.5 127.3%  
Exports to sales %3.024.8 12.3%   
Imports to sales %0.43.7 11.4%   
Exports (fob) Rs m3073,956 7.7%   
Imports (cif) Rs m43596 7.2%   
Fx inflow Rs m3074,952 6.2%   
Fx outflow Rs m125697 18.0%   
Net fx Rs m1814,255 4.3%   
CASH FLOW
From Operations Rs m11,7542,786 421.8%  
From Investments Rs m-561-1,529 36.7%  
From Financial Activity Rs m-6,762-941 718.5%  
Net Cashflow Rs m4,432316 1,400.7%  

Share Holding

Indian Promoters % 39.6 61.4 64.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.5 3.7 202.7%  
FIIs % 16.8 12.7 132.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 36.1 22.1 163.3%  
Shareholders   16,479 46,261 35.6%  
Pledged promoter(s) holding % 77.6 35.8 216.9%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ELDER PHARMA With:   TTK HEALTHCARE  ALEMBIC LTD  WYETH LTD  AJANTA PHARMA  TORRENT PHARMA  

Compare ELDER PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Strong Finish to the Week; Metal & Pharma Stocks Gain(Closing)

Indian share markets finished the trading session on a strong note amid firm Asian markets after comments from a Federal Reserve official eased worries about faster rate hikes in US.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ELDER PHARMA SHARE PRICE


Sep 12, 2016 (Close)

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ELDER PHARMA 5-YR ANALYSIS

COMPARE ELDER PHARMA WITH

MARKET STATS